Understanding pain and improving management of sickle cell disease: The PiSCES study

Journal of the National Medical Association

Volumn 97, Issue 2, 2005, Pages 183-193

  Smith, Wally R ^a   Bovbjerg, Viktor E ^c   Penberthy, Lynne T ^a   McClish, Donna K ^a   Levenson, James L ^b   Roberts, John D ^a   Gil, Karen ^d   Roseff, Susan D ^a   Aisiku, Imoigele P ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d University of North Carolina at Chapel Hill   (United States)

Author keywords

Epidemiology; Pain; Sickle cell disease; Utilization

Indexed keywords

CHRONIC PAIN; COHORT ANALYSIS; COPING BEHAVIOR; DEATH; DISABILITY; DISTRESS SYNDROME; FAMILY; HEALTH BEHAVIOR; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; MULTIPLE ORGAN FAILURE; PAIN; PAIN ASSESSMENT; PRIORITY JOURNAL; REVIEW; SICKLE CELL ANEMIA; SURVIVAL;

ADAPTATION, PSYCHOLOGICAL; ADOLESCENT; ADULT; AFRICAN AMERICANS; ANEMIA, SICKLE CELL; ATTITUDE OF HEALTH PERSONNEL; HUMANS; LONGITUDINAL STUDIES; MEDICAL RECORDS; MODELS, PSYCHOLOGICAL; PAIN; PAIN MEASUREMENT; PROSPECTIVE STUDIES; SOCIAL SUPPORT; VIRGINIA;

EID: 13444252435     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Motulsky AG. Frequency of sickling disorders in U.S. blacks. N Engl J Med. 1973;288:31.
2. Meany FJ, Riggle SM. Newborn screening report, 1990. Austin, TX: Council of Regional Networks for Genetic Services; 1992.
3. SCD Guideline Panel. SCD: Screening, Diagnosis, Management and Counseling in Newborns and Infants. Clinical Practice Guideline no. 6. AHCPR Pub. No. 93-0562. Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services. April 1993.
4. Smedley BD, Stith AY, Nelson AR, eds. Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care. Institute of Medicine, Board on Health Science Policy. 2002; National Academy Press, Washington, DC.
5. Gallaway S. et al. Sickle cell anemia-a review. J Emerg Med. 1988;6:213-226.
6. Scott RB. Health care priority and sickle cell anemia: special communication. JAMA. 1970;214:731-734.
7. Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia: a randomized trial. N Engl J Med. 1986;314:1593-1599.
8. Lee A, Thomas P, Cupidore L, et al. Improved survival in homozygous sickle cell disease: lessons from a cohort study. Brit Med J 1995;311:1600-1602.
9. Davis H, Schoendorf KC, Gergen PJ, et al. National trends in the mortality of children with sickle cell disease, 1968 through 1992. Am J Public Health. 1997;87:1317-1322.
10. Gaston MH, Rosse W. The cooperative study of sickle cell disease: review of study design and objectives. Am J Pediatr Hematol Oncol. 1982;4:197-200.
11. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in SCD. Life expectancy and risk factors for early death. N Engl J Med. 1994;330:1639-1644.
12. Wierenga KJJ, Hambleton IR, Lewis NA. Survival estimates for patients with homozygous sickle-cell disease in Jamaica: a clinic-based population study. Lancet. 2001;357:680-683.
13. Murray N, May A. Painful crises in sickle cell disease-patients' perspectives. BMJ. 1988;297:452-454.
14. Platt OS, Thorington BD, Brambilla DJ, et al. Pain in SCD. Rates and risk factors. N Engl J Med. 1991;325:11-16.
15. Baum K, Dunn DT, Maude GH, et al. The painful crisis of homozygous sickle cell disease: a study of risk factors. Arch Intern Med. 1987;147:1231-1234.
16. Andersen R. 'A behavioral model of families' use of health services: HSA studies, University of Chicago Research Series No. 25, 1968.
17. Engel GL. The need for a new medical model: a challenge for biomedicine. Science. 1977;196:129-136.
18. Wison Schaeffer J J, Gil KM, Burchinal M, et al. Depression, disease severity and sickle cell disease. J Behav Med. 1999;22:115-126.
19. Grant MM, Gu KM, Floyd MY, et al. Depression and functioning in relation to health care use in sickle cell disease. Ann Behav Med. 2000;22:149-57.
20. Gil KM, Carson JW, Porter LS, et al. Daily stress and mood and their association with pain, healthcare use, and school activity in adolescents with sickle cell disease. J Pediatr Psychol. 2003;28:363-373.
21. Gil KM, Carson JW, Porter LS, et al. Daily mood and stress predict pain, health care use and work activity in African-American adults with sickle-cell disease. Health Psychol. 2004;23:267-274.
22. Vichinsky E, Johnson CS, Lubin BH. Multidisciplinary approach to pain management in SCD. Pediatrics. 1989;84:500-508.
23. Gil KM, Carson JW, Sedway JA, et al. Follow-up of coping skills training in adults with sickle cell disease: analysis of daily pain and coping practice diaries. Health Psychol. 2000;19:85-90.
24. Gil K, Wilson J, Edens J, et al. Effects of cognitive coping skills training on coping strategies and experimental pain sensitivity in African-American adults with SCD. Health Psychol. 1996;15:3-10.
25. Kaslow NJ, Collins MH, Loundy MR, et al. Empirically validated family interventions for pediatric psychology: SCD as an exemplar. J Pediatric Psychol. 1997;22:213-227.
26. Dinges DF, Whitehouse WG, Orne EC, et al. Self-hypnosis training as an adjunctive treatment in the management of pain associated with SCD. Int J Clin Exp Hypn. 1997;45:417-432.
27. Becker MH. The Health Belief Model and personal health behavior. Health Education Monographs. 1974;2:409-419.
28. Chen M, Land K. Testing the health belief model: LISREL analysis of alternative models of causal relationships between health beliefs and preventive dental behavior. Soc Psych Quarterly. 1986;49:45-60.
29. Reese FL, Smith WR. Psychosocial determinants of health care utilization in SCD patients. Ann Behav Med. 1997;19:171-178.
30. Charache S, Terrin ML, Moore RD, et al. Investigators of the Multicenter Study of Hydroxyurea and Bonds DR. Effect of hydroxyurea on frequency of painful crises in sickle cell anemia. N Engl J Med. 1995;332:1317-1322.
31. Steinberg MH, Barton F, Castro O, et al. Effect of Hydroxyurea on Mortality and Morbidity in Adult Sickle Cell Anemia: Risks and Benefits Up to Nine Years of Treatment. JAMA. 2003;289:1645-1651.
32. Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol. 1991;133:144-153.